Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cephalon, a biopharmaceutical company, has reported a net income of $43.78 million, or $0.75 per share for the first quarter of 2009 compared to a net income of $30.44 million, or $0.41 per share for the first quarter of 2008.
Subscribe to our email newsletter
The company has reported total revenues of $519.97 million for the first quarter of 2009 compared to $443.22 million for the first quarter of 2008.
Frank Baldino Jr, chairman and CEO of Cephalon, said: “While the economy and various healthcare reform proposals create uncertainty for investors, we are taking steps to continue to build a world class biopharmaceutical company.
“In the short run, Amrix and Treanda will supply growth. Longer term, we expect that our recent business development transactions will enable us to create a new franchise in inflammatory diseases and our clinical development work with Nuvigil will allow it to reach new markets.”